Angelina Jolie’s double mastectomy and the question of who owns our genesBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3340 (Published 22 May 2013) Cite this as: BMJ 2013;346:f3340
- Richard Hurley, deputy magazine editor, BMJ
“Today it is possible to find out through a blood test whether you are highly susceptible to breast and ovarian cancer, and then take action,” the Oscar winning Hollywood actor Angelina Jolie said in the New York Times on 14 May.1 The seemingly extreme action that she took was prophylactic bilateral mastectomy. And the tests for breast cancer that she mentioned are controversial, because they are controlled by a single commercial company that has been allowed to patent the underlying genetic sequences.
Less than three weeks after her breast reconstruction the New York Times ran Jolie’s opinion article to explain why she had made her decision. “To be proactive and to minimize the risk as much I could,” the star of the Tomb Raider films wrote.1
In 1000 frank words the 37 year old described wanting to “take control of” the inherited “faulty” gene BRCA1 that she carries, the same mutation that led to ovarian cancer in her grandmother and her mother, who died aged 56. The mastectomy had reduced Jolie’s lifetime risk of breast cancer from 87% to 5%, she …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial